SciTech Development, L.L.C.

Advancing Cancer Treatment Through Safer Drug Delivery

SciTech Development, L.L.C.

Advancing Cancer Treatment Through Safer Drug Delivery

Grosse Pointe Farms, MI
Biotechnology
Health Tech
SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. We have developed a powerful, new Drug Delivery Platform (SDP) that will revolutionize how safe and promising, yet challenged drugs, can be delivered to kill cancer. SciTech has developed our first, patented drug, ST-001-nanoFenretinide that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. SciTech’s innovations will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SciTech Development is in the pre-revenue clinical stage of development.

$102,146

raised
85
Investors
$63.9M
Valuation
$2.75
Price per Share
$275.00
Min. Investment
Units
Security Type
Equity
Offering Type
$5M
Offering Max
27
Days Left

$102,146

raised
85
Investors
$63.9M
Valuation
$2.75
Price per Share
$275.00
Min. Investment
Units
Security Type
Equity
Offering Type
$5M
Offering Max
27
Days Left

Rewards

Get rewarded for investing more into SciTech Development, L.L.C.:

$275+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500+
Investment
Tier 1
Invest >$500, you will receive 5% bonus shares.
$1,500+
Investment
Tier 2
If you invest >$1,500, you will receive 10% bonus shares.
$5,000+
Investment
Tier 3
If you invest >$5,000, you will receive 15% bonus shares.
$10,000+
Investment
Tier 4
If you invest >$10,000, you will receive 20% bonus shares and an in-person** or virtual meeting with the leadership team.

Reasons to Invest

SDP, our proprietary and revolutionary Drug Delivery Platform, has enormous potential to develop and deliver new and better drugs for incurable cancers.
ST-001 (SDP plus fenretinide) is patented and clinical trial ready, with an FDA guided accelerated trial plan. Fenretinide presents a low risk scenario since it has been shown to be safe and effective in both children and adults. ST-001 is an affordable, cost-effective cancer treatment.
The market potential for ST-001 is about $2B, with an additional $5B-25B+ market potential from other targeted cancer indications, ST-001 combination therapies and from using our Delivery Platform to engineer and patent new drugs.

We Are Making A Difference

Wouldn’t it be great if every patient could “Ring the Bell” to signify the end of their cancer journey?

We are SciTech Development, a Specialty Pharmaceutical Company with the goal of helping patients end their battle with cancer.


SciTech has developed a revolutionary new Drug Delivery Platform called “SDP” to safely deliver drugs that kill cancer cells. We have used our proprietary Delivery Platform to develop our first clinical drug candidate, ST-001 nano-Fenretinide, with potentially more to follow.


We initially brought our message to Big Pharma. Although excited, they said “Come back and see us when you have some clinical data”. So, we are bringing our message directly to you through StartEngine. Funding through StartEngine will help us start clinical trials.

According to IQVIA, about 80% of the industry's drug development pipeline comes from emerging biopharma companies, which means small companies are overwhelmingly driving innovation and new drug products.

The first step to potentially curing cancer is to begin clinical trials of ST-001 for the treatment of lymphoma. Our intent is to expand the use of ST-001 in other cancers and develop additional new drugs so we can help the millions of patients that are battling cancer.

FDA approval of ST-001 would be a significant step towards becoming a revenue-generating company.


How It Works


*The above video contains computer generated demonstrations of the SciTech Drug Delivery Platform.

For more detailed technical info, visit our science-based website at  www.scitechdevelopment.com

THE PROBLEM


Cancer is an Escalating Worldwide Problem

Billions of dollars have been spent on developing new cancer therapies. And yet, there have been limited advancements in treatment and healthcare costs continue to rise.


There is an urgent need for therapies that can fight multiple cancers with high effectiveness, low side effects, and at an affordable cost. Many existing drugs are not able to achieve their full potential because they simply cannot effectively enter the cancer cell in sufficient amounts. Administering them in higher doses may not solve this problem without causing significant harm to the patient.


Patients suffering from cancer are often faced with the reality that there may be limited benefits from their existing treatment. Their cancer treatment is often fraught with long-lasting side effects from potentially harmful or toxic treatments with no cost-effective alternative therapies. Their struggle may be long and traumatic with no end in sight.


Help us try to make the struggle shorter, safer, and more cost-effective for those suffering from cancer. 



THE SOLUTION


An Effective Drug Delivery Platform for New Cancer Treatments 

We believe that ST-001 will provide hope to millions of cancer patients.



  • The SciTech Drug Delivery Platform or “SDP” is designed to safely deliver high concentrations of drugs to kill cancer cells.
  • SDP works by formulating drugs into very tiny spheres known as “nanovesicles”, which “trick” the cells into letting the drug inside, ultimately killing the cancer.
  • SDP can be engineered with other drugs, making them more effective and patentable.
  • ST-001 nanoFenretinide, our patented lead drug candidate, is a combination of the Delivery Platform and fenretinide, a drug with a well-documented safety profile.
  • ST-001 and newly engineered SDP drugs may be used alone or in combination with existing therapies.

THE MARKET


New Therapeutics for Broader and Better Clinical Outcomes

Oncology is the world’s largest pharmaceutical therapeutic area. The growing prevalence of cancer around the world will continue to spur opportunities for the oncology drug market. SciTech plans to engineer new cancer drugs for better clinical outcomes in more oncology areas and diseases.


Source


The immediate targeted market for ST-001 is estimated to be about $2 Billion.  
 
The market potential can be expanded to $5B-25B+ with ST-001 combination therapies, targeting other cancer indications, and from using our Delivery Platform to engineer and patent new drugs.  
 


According to Global Industry Analysts Inc., the global market for cancer therapies is projected to reach USD $204.2 billion by 2024 with a compounded annual growth rate (CAGR) of 9.7%. The U.S. represents the largest market for cancer therapies with an estimated 38.3% share of the total global market.

Our Traction


SciTech Anticipates a Rapid Path to Commercialization

Fenretinide: Safe with Great Promise in Previous Clinical Trials


ST-001 contains the active ingredient fenretinide, a drug with a well-documented safety profile in over 3000 patients. However, it does not easily dissolve in the body so it cannot get to the cancer cells in high enough doses to be effective, a problem solved by ST-001.


After achieving numerous milestones, our approved clinical trials are “Confirmatory” not “Exploratory”.  Our trial simply needs to confirm that ST-001 can transport the drug into the cancer cell safely, at the right dose, without toxic side effects, and provide beneficial patient outcomes.




Unlike other “typical” clinical trials, the FDA has provided SciTech with guidance to a much faster pathway requiring fewer patients.  Once the clinical trials are completed and with FDA approval SciTech will be able to commercialize ST-001.


SciTech can now  begin its clinical trial at Rush University Medical Center in Chicago, IL.


how we're different


SciTech Can Develop a Robust Commercial Pipeline Using SDP, Our Proprietary Drug Delivery Platform


  • Our revolutionary new Drug Delivery Platform (SDP) has enormous potential in developing and delivering new drugs.
  • ST-001 is clinical trial ready with a rapid path to commercialization.
  • ST-001 is an affordable cancer therapy that can reduce treatment costs and improve outcomes.
  • SciTech has an exceptional leadership and scientific advisory team with vast industry experience.



THE BUSINESS MODEL


Milestone Driven With Multiple Exit Strategies

Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies.


ST-001 would be an ideal candidate for use in combination drug/therapy regimens. The emerging trend in cancer treatment is to combine new, targeted therapies with other drugs in order to increase their effectiveness and therapeutic benefit. Use of ST-001 in this manner would have a significant positive impact on revenue.



SciTech can develop a robust pipeline of new drug candidates using our Delivery Platform, potentially increasing the valuation of the company.


All potential exit strategies will be considered, based on the best outcome for our investors, the company, and the timing of these potential options.



Due to the COVID-19 pandemic, the company is currently working virtually. We have engaged a large-scale drug manufacturer to produce ST-001 and a clinical trial site to conduct our study.

WHY INVEST


Together, We Can Fight Cancer and Bring New Hope to Patients Around the World.

First and foremost, we believe that ST-001 may drastically improve the therapeutic options for cancer patients.  Whether it's you, a family member, or a friend, just about everyone has been touched by cancer. Too many of us have too many common stories of pain and sorrow.


SciTech’s Delivery Platform provides an opportunity to develop new cancer drugs and change the cancer treatment landscape.

FDA approval of ST-001 would be a significant step toward becoming a revenue-generating company.

With our science and your help, we can provide a brighter future for patients, our partners, and our investors.


Please join us in helping to give each and every cancer patient a fighting chance to “Ring the Bell’’!


Italic (⌘I)

Offering Summary


Company

:

SCITECH DEVELOPMENT L.L.C.

Corporate Address

:

P.O. Box 36927, Grosse Pointe Farms, MI 48236

Offering Minimum

:

$9,999.00

Offering Maximum

:

$4,999,997.75

Minimum Investment Amount

(per investor)

:

$275.00











Terms


Offering Type

:

Equity

Security Name

:

Units

Minimum Number of Shares Offered

:

3,636

Maximum Number of Shares Offered

:

1,818,181

Price per Share

:

$2.75

Pre-Money Valuation

:

$63,928,290.25











*Maximum Number of Units Offered subject to adjustment for bonus units. See Bonus info below.

Company Perks

Time-Based Bonuses*:

  • Invest within the 1st week and receive 20% bonus shares.
  • Invest within the 2nd week and receive 15% bonus shares.
  • Invest within the 3rd week and receive 10% bonus shares.
  • Invest within the 4th week and receive 5% bonus shares.

Volume Based Bonuses and Perks*:

Tier 1

  • Invest >$500, you will receive 5% bonus shares. 

Tier 2

  • If you invest >$1,500, you will receive 10% bonus shares.

Tier 3

  • If you invest >$5,000, you will receive 15% bonus shares.

Tier 4

  • If you invest >$10,000, you will receive 20% bonus shares and an in-person** or virtual meeting with the leadership team.

*Investors cannot qualify for both bonuses in any single investment. If an investor qualifies for two bonuses the higher of the two bonuses will be applied. All perks occur after the offering is completed.

**Travel Not Included

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

SciTech Development LLC will offer 10% additional bonus Units for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine members will receive a 10% bonus for any units they purchase in this offering. For example, if you buy 100 Units at $2.75/unit, you will receive 110 Units, meaning you'll own 110 shares for $275. Fractional Units will not be distributed and unit bonuses will be determined by rounding down to the nearest whole unit.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”. Inter company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$295,356.00 USD
$327,348.00 USD
Cash And Cash Equivalents
$37,225.00 USD
$113,834.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$192,650.00 USD
$0.00 USD
Long Term Debt
$750,332.00 USD
$810,332.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$312,831.00 USD
$352,742.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$316,648.00 USD
-$357,642.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Campaign Closing in 28 Days!

1 day ago

Invest before it's too late! SciTech's equity crowdfunding campaign on StartEngine will be closing in 28 days.

We’ve had a phenomenal response so far from many investors like yourself who want to help patients battle their cancer. Our goal is to build a community of advocates that will help SciTech advance our lead drug candidate ST-001 through clinical trials and into the marketplace.

Don’t miss out on your chance to invest in an amazing company and its science!

Visit www.SciTechSDP.com to learn more about our revolutionary drug Delivery Platform (SDP) and our patented drug candidate ST-001 nanoFenretinide.

Glyphosate-Based Herbicides (GBHs) Increase Risk for Non-Hodgkin’s Lymphoma (NHL), SciTech’s Targeted Cancer Indication

2 days ago

Glyphosate, commonly sold under the trade names of Roundup® and Ranger Pro®, is the most widely used herbicide in the world. A recently published article provides compelling evidence that glyphosate and GBHs are a cause of non-Hodgkin’s lymphoma (NHL) in humans (https://pubmed.ncbi.nlm.nih.gov/34052177/).

Diagram

Description automatically generatedAgribusiness giant Bayer (Monsanto) recently announced that it would phase out the sale of Roundup® and GBHs for residential use (lawn and garden) starting in 2023. Bayer’s decision is intended to reduce future lawsuits related to the safety of the herbicide. GBHs will remain available for agricultural use, where American crops are treated with over 250 million pounds of glyphosate per year. (https://investigatemidwest.org/2019/05/26/breaking-down-the-use-of-glyphosate-in-the-u-s/).

A picture containing text

Description automatically generated

SciTech’s lead drug candidate ST-001 nanoFenretinide is scheduled to enter the clinic in Q4 2022 for the treatment of non-Hodgkin’s lymphoma (NHL).

To learn more visit www.SciTechSDP.com  


Notice of Material Change in Offering

4 days ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SciTech Development, L.L.C. offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign end date.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Invest in a Potential Cure for Cancer

4 days ago

 It’s always a good time to invest in a cure.

How to invest in a potential cure for cancer? Invest in SciTech.

To learn more visit www.SciTechSDP.com

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence

 

Global Oncology Trends and ST-001 nanoFenretinide

8 days ago

According to a recent report from IQVIA “Global Oncology Trends 2022”, oncology patients continue to struggle with the impact from delays in screenings, diagnoses and cancer care from COVID-19 (Institute Report, May 26, 2022).

Additional takeaways from the report include:

  • Oncology trials represent a significant portion of all clinical trials, with most trials focused on rare cancers.
  • Oncology drugs are increasingly receiving accelerated approvals, orphan or breakthrough designations.
  • More than two-thirds of novel cancer drugs have costs over $100,000 with about one-third exceeding $200,000 per year.

SciTech’s orphan-designated ST-001 nanoFenretinide oncology drug candidate is expected to be a competitive, affordable cancer treatment with an accelerated FDA approval timeline that uniquely addresses all three bullets above. ST-001 will be entering clinical trials later this year for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of cancer.

For more info, follow SciTech on Facebook and StartEngine.

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence

 

SciTech Presenting at Upcoming MedInvest Oncology Investor Conference

10 days ago

SciTech is pleased to announce that it has been invited to participate in the MedInvest Oncology Investor Conference in New York City June 28-29, 2022.

The conference will gather leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion on trends, opportunities, and risks in oncology investing. For more info about the conference, visit MedInvest.

Earle Holsapple, SciTech Co-Founder, CEO. and President, will present SciTech's lead drug candidate ST-001 nanoFenretinide and its proprietary drug delivery platform (SDP). Earle will also be available for private meetings with attendees.

For more info, follow SciTech on Facebook and StartEngine.

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence

 

SciTech Receives $750K Cash Infusion from CNR Round of Investment

12 days ago

SciTech is pleased to announce it has received an initial cash infusion of $750,000 as its first installment of its latest Convertible Note Round (CNR) of financing. This $750K represents just over one-third of the total raise of $2MM targeted and filed with the SEC (Form D filed April 26, 2022). This CNR financing complements the company's ongoing $5,000,000 equity crowdfunding campaign on StartEngine.

To date, investors have committed to provide a total of $1,850,000 of CNR debt financing during the next several months. The current round of convertible note financing is being provided primarily by two private investor groups, several individual accredited investors as well as a family fund of funds.

The debt financing will be used for the preparation and conduction of the initial clinical trial of SciTech’s new oncology drug formulation of fenretinide (ST-001 nanoFenretinide). The complementary StartEngine funding will help enable the company in scaling its management team and operations in support of the upcoming clinical trials which are designed to confirm the safety and clinical efficacy of ST-001 nanoFenretinide.

Recently Published Article Suggests SciTech's Drug Delivery Platform (SDP) as a Topical Drug Delivery System

12 days ago

A recently published article titled "Rethinking Breast Cancer Chemoprevention: Technological Advantages and Enhanced Performance of a Nanoethosomal-Based Hydrogel for Topical Administration of Fenretinide" (Apolinário, A.C., et al. AAPS PharmSciTech 23, 104 (2022) https://doi.org/10.1208/s12249-022-02257-1) concluded that ethosome fenretinide hydrogels presented technological advantages, provided sustained drug release and skin penetration supporting the potential applicability of ethosomes as topical fenretinide drug delivery systems.

Ethosomes are phospholipid nanovesicles very similar in structure to SciTech’s Drug Delivery Platform (SDP).

The recent article strongly suggests utilization of SciTech’s ST-001 nanoFenretinide (SDP + Fenretinide) as a topical fenretinide cancer treatment and especially as a treatment for skin cancer.

The recent article also suggests that SciTech's SDP technology may present out-licensing opportunities for its use as a topical drug delivery agent.

Follow SciTech on Facebook and StartEngine.


Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence


Our Community Joins In! | Insider Investment Notice

15 days ago

We’re excited to see our community come in and invest in Sci Tech Development. 

Our Insiders have invested a total of $ 2641.33 amount into the offering!

We hope you join as well! Invest in Sci Tech Development. 

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors


With ST-001 nanoFenretinide There is Hope Today for Millions

15 days ago


Cancer has touched everyone. Therapy can be brutal. With SciTech's drug candidate ST-001 nanoFenretinide, there is hope today for a bright future for millions of cancer patients.

According to Eric Topol in "A turning point in cancer", the matching of an appropriate therapy with the genomics of the cancer is leading to outcomes that are being described as “unheard-of” by expert oncologists. This is individualized medicine - the marriage of cancer genomics with targeted therapy or immunotherapy - leading to accurate & effective treatments while avoiding the toxicity of classical chemotherapeutics.

Why is this important to SciTech? There remain limitations with the implementation, use and applicability of this approach; particularly regarding patient affordability and the need to develop costly multiple medications for a single cancer indication, individually tailored for each type of cancer.

Although the use of genomics in identifying cancer immunotherapies and targeted therapies is exciting and promising, it is simply not currently available as a cost-effective therapy for a broad spectrum of cancer patients.

With a well-documented safety profile that lacks the toxicity associated with chemotherapeutics, ST-001 presents an affordable and widely applicable cancer treatment that is available today.

Visit www.SciTechSDP.com to learn more and to become an investor in our mission to cure cancer.

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence

 

 

 

SciTech Advisory Board Member Named Top Medical Oncologist

17 days ago

SciTech Advisory Board Member Timothy Kuzel, MD, FACP, was recently named a top medical oncologist by Chicago magazine, June 7, 2022.

Dr. Kuzel is the Samuel G Taylor III MD Professor of Oncology and Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College. He is also Chief, Division of Hematology, Oncology and Cell Therapy & Interim Deputy Director at Rush Cancer Center.

Dr. Kuzel has previously received the American Cancer Society Clinical Oncology Career Development Award and has been a recipient of teaching awards from the Division of Hematology/Oncology of the Feinberg School of Medicine at Northwestern University. He has authored or co-authored over 250 journal articles, editorials, and book chapters and has edited several textbooks.

We are excited that Dr. Kuzel will be the Principal Investigator (PI) of SciTech’s clinical trial of ST-001 nanoFenretinide for the treatment of T-cell non-Hodgkin's lymphoma (ClinicalTrials.gov Identifier: NCT04234048).

For more info, follow SciTech on Facebook and StartEngine.

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence


SciTech Surpasses $100K Milestone in Committed Investments

19 days ago

Thanks to your support, we have raised over $100K in committed investments since our launch on StartEngine! SciTech is on track to reach the goal of bringing its promising lead oncology drug ST-001 nanoFenretinide into human clinical trials later this year. The objective of the clinical trial is to confirm the safety and efficacy of ST-001 which should lead to rapid commercial approval by the FDA.

Spread the word about this amazing investment opportunity which is available to all types of investors.

Together, we can fight cancer and bring new hope to patients around the world.

You can follow our equity crowdfunding campaign and invest here.

Please follow us on Facebook and StartEngine.


Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence


SciTech Announces Manufacturing Partnership With The Plough Center

22 days ago

SciTech Development is pleased to announce that it has signed a letter-of-intent (LOI) to manufacture its lead cancer drug candidate ST-001 nanoFenretinide at The Plough Center for Sterile Drug Delivery Systems.

The Plough Center is a Memphis Tennessee manufacturing company affiliated with the University of Tennessee Health Science Center that assists universities, scientific communities and industry in the manufacture and delivery of therapeutic advances that will improve patient standard of care.

By entering into this drug manufacturing partnership, SciTech moves one step closer to dosing its first patient in its Phase 1 clinical trial.

To learn more, follow us on Facebook and StartEngine.

 

Graphical user interface, application, Word

Description automatically generated

Text

Description automatically generated with low confidence

 

 

 

An Investment That Can Make a Difference

24 days ago

How often do we learn that a person close to us has been diagnosed with cancer or has succumbed to it? Sadly, the answer is “way too often.” During those times, we wish we could do something, yet we find ourselves left with a sense of helplessness.

An investment in SciTech will give you the opportunity to take meaningful action against cancer and become part of the solution for millions of people.  Please take a minute to review the information posted throughout our StartEngine page and website to learn more about SciTech and our amazing science. See why our current investors believe in SciTech and the enormous potential to change the oncology landscape.

Please join us by making an investment in SciTech so that we may bring our promising cancer drug candidate into the clinic to start our first clinic trial. You can make your investment in SciTech here.

You truly can make a difference in the fight against cancer!


Ring the Bell for National Cancer Survivors Day

26 days ago

Sunday June 5th was the 35th annual National Cancer Survivors Day. National Cancer Survivors Day is an international event celebrated on the first Sunday in June. It is a day of celebration for all cancer survivors as well as for their friends and families. It is also a day to raise awareness of cancer and how it affects lives.

National Cancer Survivors Day was established to recognize and celebrate those who have battled cancer and won, and, to help bring hope to those still battling this terrible disease.

Please join with SciTech in the fight against cancer. Learn how SciTech's lead cancer drug can battle cancer here.

There’s Still Time to Invest!

about 1 month ago

Last month, in accordance with SEC regulations, Scitech updated its SEC filing to include our most recent financial statements and to extend our crowdfunding campaign. This normal annual event triggered a reconfirmation process for our Start Engine campaign investors. As a result, a few of our investors failed to reconfirm their investments.

Given this material change, the SEC requires all outstanding investors (i.e., investors who have not been vested) to reconfirm their investment.

For those of you who re-confirmed, thank you for helping SciTech achieve its funding goals to advance ST-001 into its first clinic trial and beyond.

For any investor who missed the reconfirmation deadline and had their investment subsequently canceled, you can still submit a new investment by visiting our campaign page here: https://www.startengine.com/scitechdevelopment

Happy Clinical Trials Day!

about 1 month ago

Today is National Clinical Trials Day (May 20). Clinical Trials Day was launched in 2005 to commemorate the day when James Lind started the first clinical trial (May 20, 1747) which laid the foundation for modern clinical research.

James Lind (4 October 1716 – 13 July 1794) was a Scottish doctor in the Royal Navy. By conducting one of the first ever clinical trials, he developed the theory that citrus fruits cured scurvy.

You can learn all about SciTech’s Phase 1 Clinical Trial of ST-001 nanoFenretinide for the treatment of  T-cell Non-Hodgkin Lymphoma here.

SciTech's Fenretinide Drug Candidate Likely to Have Applications in Pediatric Cancer

about 2 months ago


Help us make a difference in the fight against cancer!

Pediatric cancer or childhood cancer is a devasting prognosis for patients and their families. Although great progress has been made in the treatment of certain pediatric cancers, the prognosis for some childhood cancers can effectively be a death sentence.

Lou Scarmoutzos, Ph.D., Senior Scientist and COO at SciTech Development has recently posted an article about the use of the drug fenretinide as an experimental treatment in certain types of childhood cancers, including some of the most aggressive cancers. The article provides an overview of the use of fenretinide in select preclinical and clinical studies of alveolar rhabdomyosarcoma (ARMS), diffuse intrinsic pontine glioma (DIPG), Ewing's sarcoma, hepatoblastoma, leukemia, neuroblastoma, rhabdoid tumors, solid tumors, head and neck squamous cell carcinoma (HNSCC), and non-Hodgkin's lymphoma (NHL). 

The article includes the use of fenretinide as a monotherapy or as a co-therapy in a multiple or combination treatment regimen. To read more, visit  www.SciTechDevelopment.com/fenretinide-pediatric-cancer

Your investment in SciTech may bring us one step closer to finding a cure for many different types of cancer.

2021 Annual Report Available

about 2 months ago


SciTech announces that it has recently submitted 2021 Form C-AR (Annual Report) and 2021 audited financials to the U.S. Securities and Exchange Commission (SEC), as required by the SEC Regulation Crowdfunding (CF) rules.

SciTech’s 2021 audited financial statements were conducted by Baird, Cotter & Bishop P.C. (Cadillac, MI) and certified to be in accordance with generally accepted accounting principles and represented fairly, in all material respects, the financial position of SciTech Development as of December 31, 2021.

You can view SciTech’s audited financial statements and SEC filings here.

More Reasons to Invest in SciTech

about 2 months ago


SciTech Intends to Raise an Additional $2,000,000 to Fund Clinical Trials

2 months ago

SciTech recently filed a Form D with the SEC indicating its intention to raise an additional $2,000,000 of Convertible Note Round (CNR) financing from accredited investors. This debt financing will be used to jumpstart the company’s initial clinical trial to confirm the safety of its lead drug fenretinide in its new intravenous nanoparticle formulation (ST-001 nanoFenretinide).

A CNR investment is beneficial to existing investors because the additional financial resources allows SciTech to achieve its goals in a more timely fashion, thereby potentially providing investors a more timely return on their investment.

An additional benefit is that it further validates SciTech's technology and business model since sophisticated, accredited investors are willing to invest larger sums of money. Also, the addition of CNR investors does not affect company valuation or provide CNR investors with voting rights.

Notice of Material Change in Offering

2 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SciTech Development, L.L.C. offering. Here's an excerpt describing the specifics of the change:


The campaign is extending its end date by 60 days and updating its financials to 2020/2021


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Kevin Price, host of the “Price of Business” radio program, interviews SciTech's David Schaffer

2 months ago

Recently Kevin Price, host of the nationally syndicated “Price of Business” radio program, interviewed David Schaffer, Director of Investor Relations at SciTech Development. We’d like to thank those who were able to tune in and listen live to this informative interview. While the Price of Business is nationally syndicated we understand many of you were not able to listen in so for those who weren’t, please take a moment to catch it here.

SciTech Exceeds First Funding Milestone

2 months ago

Fenretinide Reported Most Promising Drug in Oncology Pipeline

2 months ago

Nearly 20 years ago, fenretinide was reported to be the most promising cancer drug in the oncology pipeline (Nicole Gray, Pharmaceutical Executive, "Predicting Success: A Pipeline Report". December 1, 2003). What happened to fenretinide? To date, fenretinide’s lack of commercialization has been hampered by its inherently poor bioavailability, until now with SciTech’s introduction of ST-001 nanoFenretinide. 

From “Pharmaceutical Executive (December 1, 2003)” https://www.pharmexec.com/view/predicting-success-pipeline-report:

"Fenretinide. An oral compound for breast cancer being developed by Ortho-McNeil and the National Cancer Institute leads with a rating of 85. Fenretinide is a synthetic retinoid that has demonstrated efficacy as a chemotherapeutic agent in women with early-stage breast cancer. In a five-year study of 2,972 women with stage-one breast cancer, premenopausal women who were treated with fenretinide experienced a reduced incidence of local recurrence and contralateral development of breast tumors relative to their placebo- treated counterparts. Yet, that finding did not hold true for postmenopausal women."

"In a separate analysis of 2,867 women with early breast cancer, women treated with 200mg of fenretinide once daily for five years had a significantly lower risk of ovarian cancer compared with placebo-treated controls (0 vs. 6 cases). However, the effect only lasted for the duration of the intervention. Fenretinide has also been evaluated in conjunction with tamoxifen therapy, and the combination has shown positive results. In some cases, the regimen resulted in partial or complete remissions and disease stabilization."

Based on solid clinical studies in thousands of patients and a well-documented safety profile, fenretinide continues to have enormous potential as a cancer therapeutic. SciTech offers new life for the promising cancer drug fenretinide in its patented lead drug candidate ST-001 nanoFenretinide.

SciTech to be Interviewed on Nationally Syndicated “The Price of Business” Radio Show

3 months ago


David Schaffer, Director of Investor Relations at SciTech Development, will be interviewed by Kevin Price, host of The Price of Business radio show. The show airs on Bloomberg 1110 AM radio in Houston, TX and is syndicated nationally to 16 other Bloomberg stations. The show is a business-focused radio program that reaches more than 100,000 listeners weekly with thousands more via streaming online audio.

David will be interviewed on April 18, 2022, with the show being aired later that week on 1110 AM Radio (Houston, TX). The interview will include a discussion on SciTech Development and its science, the company’s proprietary drug candidate and its commercialization stage, recent milestones, and future challenges.

SciTech Poster Presentation at the American Society of Hematology (ASH) Annual Conference

3 months ago

SciTech’s poster presentation at ASH provided an overview of the company’s FDA-approved Phase 1 clinical trial of ST-001 nanoFenretinide for the treatment of patients with T-cell non-Hodgkin's lymphoma (NHL). 

Poster Presentation takeaways include:

  • Clinical details of treating NHL patients including ST-001 nanoFenretinide drug dosing levels, frequency of dosing, number of patients to be treated, and duration & evaluation of the drug treatment.
  • The composition of SciTech's ST-001 nanoFenretinide drug formulation including an overview of the ST-001 drug manufacture.
  • The objectives of the clinical plan including evaluation of the highest drug dose achievable in patients (maximum tolerated dose, MTD), potential side effects and clinical pharmacology.
  • Hypothesized structure of the ST-001 nanoparticle.
  • Preclinical data and testing that provides support and justification for entering the clinic with ST-001 nanoFenretinide as an anticancer drug.

An abstract of the poster presentation can be found at: https://ashpublications.org/blood/article/134/Supplement_1/4041/424342/A-Phase-1a-1b-Trial-of-ST-001-a-Fenretinide 

An expanded view of the poster can be found at: https://www.scitechdevelopment.com/photos?pgid=k10qt7si-a9170c7a-57ba-4af6-a3c0-c09e6f3c2b97

 

SciTech in the News

3 months ago

William Werkmeister, SciTech Advisory Board Member, recently posted an article about SciTech Development in an investor newsletter. The article titled "SciTech Set to Advance ST-001 nanoFenretinide to Clinical Trials" can be viewed at  https://www.medinvestconferences.com/post/scitech

Fenretinide: An Overview of the Drug’s History, Properties & Uses

3 months ago


Lou Scarmoutzos, Ph.D., Senior Scientist and COO at SciTech Development has recently posted an article about fenretinide (4-HPR), the active ingredient in SciTech Development's lead oncology drug candidate ST-001 nanoFenretinide. The article discusses the history of fenretinide, its properties and applications.  To read more, visit  www.SciTechDevelopment.com/fenretinide

 

SciTech Co-Founder, Inventor, and Chief Scientific Advisor Will Be a Featured Speaker at Upcoming Pharma & Biotech Investment Conference

3 months ago

SciTech is pleased to announce that its Co-founder, Chief Scientific Advisor and Inventor, Ralph Parchment, Ph.D., will be a featured speaker at the MedInvest Pharmaceutical & Biotechnology Investor Conference taking place on March 30 - 31. In his role as the director of a multi-laboratory program at Frederick National Laboratory for Cancer Research, that is operated on behalf of the National Cancer Institute, he will be speaking on the subject of “Pharmacodynamics in Drug Discovery and Development.”

Visit www.SciTechDevelopment.com to learn more about SciTech’s Team and Technology

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}